Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFB002 for macular edema secondary to BRVO
CTR20131202Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in branch retinal vein occlusion (BRVO), sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on CTR20131202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131202.